Key takeaways
Yes, you can take Ozempic after gastric bypass or gastric sleeve surgery to lose more weight or prevent weight gain.
Ozempic produces an average weight loss of up to 15% in people who regained weight after bariatric surgery or had more weight to lose.
While the timing varies by person, research suggests it’s safe to start Ozempic at least six months after bariatric surgery, or whenever weight loss begins to plateau.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Yes, you can take Ozempic after gastric bypass or gastric sleeve surgery to lose more weight or prevent weight gain.
Ozempic produces an average weight loss of up to 15% in people who regained weight after bariatric surgery or had more weight to lose.
While the timing varies by person, research suggests it’s safe to start Ozempic at least six months after bariatric surgery, or whenever weight loss begins to plateau.
Bariatric surgery is one of the most effective treatments for weight loss, with people who undergo gastric bypass losing an average of about 70% of their excess body weight. Even so, many people have more weight to lose after surgery, and up to one in four experience weight regain. Is Ozempic after gastric bypass an option?
The emerging research suggests yes. Read on to learn how Ozempic (semaglutide) may be a viable option for weight management after gastric sleeve or gastric bypass surgery.
Can you take Ozempic after gastric bypass or gastric sleeve surgery?
Yes, you can take Ozempic after gastric sleeve or gastric bypass surgery — assuming you don’t have any contraindications that would make it unsafe. Research suggests GLP-1 medications like Ozempic can help people lose about two-thirds of the weight they regain after gastric bypass, gastric sleeve, or gastric banding surgery.
While Ozempic is approved by the US Food and Drug Administration (FDA) for type 2 diabetes, it is often prescribed off-label for weight loss because its active ingredient, semaglutide, produces significant weight loss. Semaglutide is also the active ingredient in Wegovy, a higher-dose weight loss medication. Ozempic and Wegovy support weight loss by:
Slowing digestion
Preventing blood sugar spikes
Reducing appetite and food cravings
Boosting feelings of fullness
Here’s a look at the research on Ozempic after bariatric surgery:
Ozempic drives additional weight loss post-surgery. A small study of 29 people who had either regained weight or had more to lose after gastric bypass and gastric sleeve surgery were prescribed a 1 mg dose of Ozempic for one year. They lost nearly 15% of their body weight. Another study found Ozempic produced a typical weight loss of 7.5% over 6–12 months.
Ozempic may be more effective than other GLP-1 medications like liraglutide. A study of 207 people who regained weight after gastric bypass, gastric sleeve, or gastric banding were prescribed Ozempic or Saxenda (liraglutide) for one year. The people taking Ozempic lost nearly 13% of their body weight, compared with almost 9% for those on Saxenda.
Ozempic may help people lose weight again relatively quickly. A study of 44 people who had regained about 12% of their body weight back after gastric bypass or gastric sleeve surgery were prescribed Ozempic. After three months, they had lost about 6% of their body weight. After six months, they had lost more than 10%.
When to take Ozempic after gastric bypass or gastric sleeve surgery
Some people can safely start Ozempic somewhere between six months and 1.5 years after gastric bypass or gastric sleeve surgery. At that point, the body has had sufficient time to heal, and your healthcare provider can assess how much weight you may still want or need to lose.
How soon you can take Ozempic after gastric sleeve or bypass surgery will depend on your personal health situation and recovery times. Some people may not start Ozempic until several years later, depending on when weight regain occurs. In some studies, participants started Ozempic nearly a decade after their surgery.
Not everyone needs to take weight loss medication following weight loss surgery. Peak weight loss typically occurs within 18–24 months after surgery, with outcomes varying with the specific type of procedure. However, some research suggests it might be beneficial to start Ozempic once weight loss begins to plateau — rather than waiting until weight regain occurs.
How effective is Ozempic for weight regain after bariatric surgery?
Several studies have shown that Ozempic is effective for addressing weight regain after bariatric surgery. After one year on Ozempic, people have lost between 13% and 15% of their body weight. In one study of people who had regained roughly 12% of their body weight after surgery, taking Ozempic led to an average 6% weight loss at three months and 10% at six months.
Risks and side effects of Ozempic after gastric bypass
Research suggests that the side effects of Ozempic after gastric bypass are similar to those experienced by people who haven’t undergone weight loss surgery. These are usually mild to moderate gastrointestinal (GI) side effects, which tend to lessen over time as the body adjusts to the medication.
Common side effects of Ozempic after bariatric surgery may include:
Nausea
Vomiting
Diarrhea
Abdominal pain
Constipation
Headache
The risks of taking Ozempic include rare but serious side effects such as:
Pancreatitis
Diabetic retinopathy (vision loss or changes) or hypoglycemia (low blood sugar) in people with type 2 diabetes
Kidney or gallbladder problems
Allergic reactions to the medication
Severe gastrointestinal reactions
Pulmonary aspiration during general anesthesia or deep sedation
If you experience more serious side effects of Ozempic, contact your healthcare provider promptly.
Can you take other weight loss medications after bariatric surgery?
Yes, other weight loss medications can be taken after bariatric surgery, including GLP-1 injections and prescription weight loss pills. The right medication will depend on your weight loss goals, other health conditions, other medications you take, and your insurance coverage. Your healthcare provider can help you review your options.
GLP-1 medications
GLP-1 medications may help people safely lose about two-thirds of their post-surgery weight regain, research suggests. Most post-bariatric surgery research to date has studied injectable forms of GLP-1 medications; more studies are needed to confirm how oral options compare. In addition to Ozempic, other GLP-1 medications include:
Liraglutide (Saxenda): Among people who lost less than 20% of their body weight at least one year post-bariatric surgery, this daily injection drove an additional 9% weight loss in six months. Other studies found the same degree of weight loss over 12 months.
Tirzepatide (Zepbound, Mounjaro): Among people who underwent a sleeve gastrectomy or Roux-en-Y gastric bypass, this weekly injection produced an average 12% weight loss in six months.
Higher-dose semaglutide (Wegovy): Wegovy is currently being studied in people who have undergone bariatric surgery. In people who haven’t had the surgery, the 2.4-mg weekly injection produced an average weight loss of 10%–16% over 68 weeks. It’s also available as a daily pill, with research suggesting similar weight loss results. An even higher dose version, Wegovy HD 7.2 mg, was recently approved by the FDA and has led to an average weight loss of nearly 19% over 72 weeks.
Prescription weight loss pills
Weight loss pills have also been studied in people who have undergone gastric bypass or gastric sleeve surgery. Some of the more effective options include:
Phentermine/topiramate (Qsymia): People taking this daily pill after bariatric surgery lost an additional 8 pounds in three months.
Phentermine (Lomaira): People taking phentermine after surgery lost another 13 pounds in three months.
Orlistat (Xenical, Alli): This three-times-daily pill helped people whose weight loss plateaued after gastric band surgery lose an additional 17 pounds in eight months. Those who made dietary changes alone, on the other hand, lost fewer than 7 pounds.
Naltrexone/bupropion (Contrave): While this medication hasn’t been studied in people who have undergone gastric sleeve or bypass surgery, it produces about 5% more weight loss than a placebo over one year.
What to discuss with your healthcare provider before trying Ozempic after gastric bypass
If you’re interested in trying Ozempic after gastric bypass, here are some questions you might want to ask your healthcare provider:
What are the risks of taking Ozempic, given my health history?
How can Ozempic further my health goals?
What eating plan should I follow to ensure I meet my nutritional needs on a reduced appetite?
Are any medications I’m taking contraindicated with Ozempic?
What other lifestyle changes should I implement before or in addition to taking Ozempic?
Is there another weight loss medication that could be a better fit for me (or more likely to be covered by my insurance)?
Should I work with other health professionals, such as a registered dietitian or personal trainer?
Bottom line
Weight regain is a common experience for people who undergo bariatric surgery. Ozempic and similar medications can be an effective option for losing weight — and keeping it off.
Many people can safely take Ozempic after gastric bypass or gastric sleeve surgery.
Research shows that Ozempic can drive significant weight loss after surgery (up to 15%), and may do so quickly — within a year or less.
In studies, people started taking Ozempic at least six months after their bariatric surgery, with some research suggesting it’s best to start it once weight loss plateaus.
Ozempic’s side effects are mostly gastrointestinal in nature, including nausea and diarrhea.
Other weight loss medications that have been studied in people after bariatric surgery include GLP-1 medications (liraglutide, tirzepatide, semaglutide) and other weight loss pills (phentermine/topiramate, phentermine, orlistat, naltrexone/bupropion).
Frequently asked questions (FAQs)
Who is not a candidate for Ozempic?
Ozempic should not be taken by people with a personal or family history of certain thyroid cancers, including multiple endocrine neoplasia syndrome type 2 (MEN2) or medullary thyroid carcinoma (MTC). It should also not be taken by anyone who is pregnant or breastfeeding.
What medications are off-limits after gastric bypass?
Your healthcare provider will let you know if you need to avoid any medications or adjust your dosage after gastric bypass. Some of these may include nonsteroidal anti-inflammatory drugs (NSAIDs), blood thinners, and antiplatelet medications.
What is the fastest way to lose weight after gastric bypass?
To continue losing weight after gastric bypass, regular exercise and changes to eating habits are recommended, such as eating smaller portions, reducing fatty foods, and increasing protein intake. Research suggests GLP-1 medications like Ozempic can also support significant weight loss after surgery.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Saxenda Important Safety Information: Read more about serious warnings and safety info.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
References
Arterburn, D. E., Telem, D. A., Kushner, R. F., et al. (2020). Benefits and risks of bariatric surgery in adults. JAMA, 324(9), 879. doi: 10.1001/jama.2020.12567. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32870301/
Athanasiadis, D. I., Martin, A., Kapsampelis, P., et al. (2021). Factors associated with weight regain post-bariatric surgery: a systematic review. Surgical Endoscopy, 35(8), 4069–4084. doi: 10.1007/s00464-021-08329-w. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33650001/
Clapp, B., Ponce, J., Corbett, J., et al. (2024). American Society for Metabolic and Bariatric Surgery 2022 estimate of metabolic and bariatric procedures performed in the United States. Surgery for Obesity and Related Diseases, 20(5), 425–431. doi: 10.1016/j.soard.2024.01.012. Retrieved from https://www.soard.org/article/S1550-7289(24)00036-4/fulltext
Dutta, D., Nagendra, L., Joshi, A., et al. (2024). Glucagon-Like peptide-1 receptor Agonists in Post-bariatric surgery patients: A systematic review and meta-analysis. Obesity Surgery, 34(5), 1653–1664. doi: 10.1007/s11695-024-07175-8. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38502519/
Ferguson, J., Fisher, O., Talbot, M., et al. (2025). Effectiveness of adjuvant semaglutide following bariatric metabolic surgery. Obesity Surgery, 35(3), 694–700. doi: 10.1007/s11695-025-07703-0. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11906545/
Jensen, A. B., Renström, F., Aczél, S., et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Obesity Surgery, 33(4), 1017–1025. doi: 10.1007/s11695-023-06484-8. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9918402/
Kommu, S. & Whitfield, P. (2024). Semaglutide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK603723/
Lautenbach, A., Kantowski, T., Wagner, J., et al. (2023). Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post‐bariatric treatment failure. Clinical Obesity, 13(5), e12593. doi: 10.1111/cob.12593. Retrieved from https://onlinelibrary.wiley.com/doi/10.1111/cob.12593
Lautenbach, A., Wernecke, M., Huber, T. B., et al. (2022). The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. Obesity Surgery, 32(10), 3280–3288. doi: 10.1007/s11695-022-06211-9. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9532334/
Lorico, S. & Colton, B. (2020). Medication management and pharmacokinetic changes after bariatric surgery. Canadian Family Physician, 66(6), 409–416. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7292522/
Lucas, E., Simmons, O., Tchang, B., et al. (2023). Pharmacologic management of weight regain following bariatric surgery. Frontiers in Endocrinology, 13, 1043595. doi: 10.3389/fendo.2022.1043595. Retrieved from https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1043595/full
Mok, J., Adeleke, M. O., Brown, A., et al. (2023). Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery. JAMA Surgery, 158(10), 1003. doi: 10.1001/jamasurg.2023.2930. Retrieved from https://jamanetwork.com/journals/jamasurgery/fullarticle/2807724
Murvelashvili, N., Xie, L., Schellinger, J. N., et al. (2023). Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity, 31(5), 1280–1289. doi: 10.1002/oby.23736. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12398307/
Noria, S. F., Shelby, R. D., Atkins, K. D., et al. (2023). Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment. Current Diabetes Reports, 23(3), 31–42. doi: 10.1007/s11892-023-01498-z. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9906605/
Pratama, K. G., Nugroho, H., Hengky, A., et al. (2024). Glucagon-like peptide-1 receptor agonists for post-bariatric surgery weight regain and insufficient weight loss: A systematic review. Obesity Medicine, 46, 100533. doi: 10.1016/j.obmed.2024.100533. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S2451847624000034?via%3Dihub
Sohan, P. R., Mahakalkar, C., Kshirsagar, S., et al. (2024). Long-Term Effectiveness and Outcomes of Bariatric Surgery: A Comprehensive review of current evidence and emerging trends. Cureus, 16(8), e66500. doi: 10.7759/cureus.66500. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11381104/
Stoll, F., Kantowski, T., Laaser, J., et al. (2025). Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition. Obesity Research & Clinical Practice, 19(1), 63–69. doi: 10.1016/j.orcp.2025.02.004. Retrieved from https://www.sciencedirect.com/science/article/pii/S1871403X25000213?via%3Dihub
U.S. Food and Drug Administration (FDA). (2025). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
U.S. Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use / Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf














